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Objective: To characterize the EndoC-bH1 cell line as a model for human beta cells and evaluate its beta cell functionality, focusing on insulin
secretion, proliferation, apoptosis and ER stress, with the objective to assess its potential as a screening platform for identiﬁcation of novel anti-
diabetic drug candidates.
Methods: EndoC-bH1 was transplanted into mice for validation of in vivo functionality. Insulin secretion was evaluated in cells cultured as
monolayer and as pseudoislets, as well as in diabetic mice. Cytokine induced apoptosis, glucolipotoxicity, and ER stress responses were
assessed. Beta cell relevant mRNA and protein expression were investigated by qPCR and antibody staining. Hundreds of proteins or peptides
were tested for their effect on insulin secretion and proliferation.
Results: Transplantation of EndoC-bH1 cells restored normoglycemia in streptozotocin induced diabetic mice. Both in vitro and in vivo, we
observed a clear insulin response to glucose, and, in vitro, we found a signiﬁcant increase in insulin secretion from EndoC-bH1 pseudoislets
compared to monolayer cultures for both glucose and incretins.
Apoptosis and ER stress were inducible in the cells and caspase 3/7 activity was elevated in response to cytokines, but not affected by the
saturated fatty acid palmitate.
By screening of various proteins and peptides, we found Bombesin (BB) receptor agonists and Pituitary Adenylate Cyclase-Activating Polypeptides
(PACAP) to signiﬁcantly induce insulin secretion and the proteins SerpinA6, STC1, and APOH to signiﬁcantly stimulate proliferation.
ER stress was readily induced by Tunicamycin and resulted in a reduction of insulin mRNA. Somatostatin (SST) was found to be expressed by 1%
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Conclusions: Overall, the EndoC-bH1 cells strongly resemble human islet beta cells in terms of glucose and incretin stimulated insulin secretion
capabilities. The cell line has an active cytokine induced caspase 3/7 apoptotic pathway and is responsive to ER stress initiation factors. The cells’
ability to proliferate can be further increased by already known compounds as well as by novel peptides and proteins. Based on its robust
performance during the functionality assessment assays, the EndoC-bH1 cell line was successfully used as a screening platform for identiﬁcation
of novel anti-diabetic drug candidates.
 2017 Novo Nordisk A/S. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The insulin producing beta cell is central in the etiology of human
diabetes as beta cell failure is the major determining factor for pro-
gression from impaired glucose tolerance to overt diabetes [1]. The
beta cell is by nature a highly metabolic active cell type and thus
particularly sensitive to further stress, e.g. dietary stress with exces-
sive glucose and fatty acids. Such high levels of glucose and lipids
initially cause stress that may escalate to toxicity, especially if these
factors act in combination with the high oxidative environment inside
the beta cell. The cellular mechanism for this glucolipotoxicity is
initially believed to be stress of the endoplasmic reticulum, but, if
sustained, it can also lead to apoptosis mediated beta cell death [2].
Given the current increase in the number of obese people, more type 2
diabetic patients are emerging. To treat this condition, increased
knowledge of the cellular and molecular mechanisms causing human
beta cell failure is warranted.
To date, the major drugs for diabetes treatment are metformin, sul-
fonylurea, insulin, insulin analogs, GLP1-analogs, as well as DPP4 and
SGLT2 inhibitors. As these drugs are so efﬁcient in blood glucose
regulation, the next innovative step could be towards a cure for dia-
betes. Therefore, new potent antidiabetic drugs are needed, and an-
alyses using human beta cells are a necessity as the majority of in vitro
research so far has been done on islets and cell lines from rodents with
only sporadic follow-up using human islets, a natural consequence of
the scarcity and the variable quality of human islets available for
research [3]. Excitingly, with the human beta cell line EndoC-bH1 [4], it
is becoming clear that we may have a robust, valid and useful human
beta cell line available for studying human beta cell physiology [5e8].
Accordingly, all in vitro data from the original publication by Philippe
Ravassard et al. have now been conﬁrmed by independent labora-
tories. Thus the identiﬁed infection with the B10 xenotropic virus 1
(Bxv1), which is a xenotropic endogenous murine leukemia virus, does
not appear to hamper proper functionality of the cell line [9].
However, the studies using EndoC-bH1 have so far been focused on
general characterization and comparison to the commonly used beta
cell models [10] and much less on the applicability of the cell line for
screening purposes.
At Novo Nordisk A/S, we performed a thorough phenotypic validation of
the cells including: transplantation to diabetic mice, static and dynamic
insulin secretion assays using both standard adherent cultures and
pseudoislet aggregates, validation of GLP1 receptor (GLP1R) func-
tionality, mRNA expression of selected beta and non-beta cell genes in
single cells and in pools over time, as well as assessing the protein
levels of the pancreatic hormones. Subsequently, we used the cell line
to establish medium through-put screening assays for the identiﬁca-
tion of drugs enhancing beta cell functionalities: glucose stimulated
insulin secretion (GSIS), proliferation, resistance to cytokine or gluco-
lipotoxicity induced apoptosis and ER stress. We observe that this
human background is a major step forward for all assays but especiallyMOLECULAR METABOLISM 8 (2018) 144e157  2017 Novo Nordisk A/S. Published by Elsevier GmbH. This is an
www.molecularmetabolism.comimportant for proliferation given the substantial lack of correlation
between data obtained in rodent versus human beta cells [11,12].
To generate a prioritized list of potential novel drug candidates, we
developed a bioinformatic pipeline exploiting both public and in-
house generated datasets (for details see Suppl. M&M). We then
produced or acquired more than 200 proteins and peptides and
performed an arrayed screen where each of the drug candidates was
tested in at least four independent biological replicates at three
different concentrations. Overall, we identiﬁed several peptides and
proteins that increase insulin secretion and proliferation, and we
report that insulin secretion is increased by the PACAP as well as
four different BB receptor agonistic peptides. Moreover, that the
proteins SerpineA6, STC1, and APOH stimulate proliferation of the
EndoC-bH1 cell line.
2. MATERIALS AND METHODS
2.1. In vivo experiments
SCID/beige mice were used for the in vivo experiments and trans-
plantation was performed when the mice were 8e10 weeks of age.
The animals were bred by Taconic Biosciences and kept at Novo
Nordisk in accordance with our standard animal unit procedures. All
experiments were approved by the Danish ethical committee for ani-
mal experiments.
EndoC-bH1 cells or human islets were transplanted under the kidney
capsule of diabetic and non-diabetic mice. Diabetes was induced by
multiple low dose streptozotocin (STZ) injections. Glucose tolerance in
non-diabetic animals was tested by intraperitoneal glucose tolerance
test (IPGTT) using 3 g/Kg glucose. Blood glucose and human C-peptide
were measured in all animals. After the experiments, the animals were
euthanized by cervical dislocation; kidneys were isolated, ﬁxed, and
analyzed by histology and immunohistochemistry. For detailed infor-
mation, see Supplementary Materials and Methods.
2.2. Immunohistochemical staining of kidneys grafted with EndoC-
cells
The isolated grafted kidneys were ﬁxed in 10% natural buffered
formalin for 24 h and processed to parafﬁn. Graft morphology was
visualized with hematoxylin and eosin staining on 3 mm sections. The
slides were scanned on a Nanozoomer 2.0-HT (Hamamatsu) at 40
magniﬁcation. The sections were stained with primary and secondary
antibodies, counterstained with DAPI and scanned. For detailed in-
formation, see Supplementary Materials and Methods.
2.3. Human islets
Human islets from cadaver donors were provided by Prodo Labora-
tories Inc., CA, USA, with informed consent from the relatives of the
deceased individuals. All experiments were done in agreement with
national legislation and institutional ethical rights. The islets were
cultured in CMRL1066 medium (Gibco) supplemented with 2 mMopen access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 145
Original ArticleGlutamine, 10% FCS (Gibco) and 1% Penicillin/Streptomycin (Gibco) at
37 C and 5% CO2.
2.4. EndoC-bH1 monolayer cell culture and pseudoislets
The cell line was cultured as previously described [4]. To generate
EndoC-bH1 pseudoislets, 10 mM ROCK inhibitor (Sigma), and 50 mg/ml
DNase (Roche) were added to 7.5  106 EndoC-bH1 cells in 10 ml
culture medium, then placed in 10 cm Corning Ultra Low attachment
dishes and aggregated for 4e5 days at 37 C and 5% CO2 on an
orbital shaker running at 50 rpm. The pseudoislets were continuously
kept like this and used for experiments until day 7.
2.5. Live-dead assay on EndoC-bH1 pseudoislets
Pseudoislets were stained with calcein for detection of esterase activity
and ethidium homodimer-1 to indicate loss of plasma membrane
integrity (Thermo Fisher Scientiﬁc). Scanning was performed on a
ﬂuorescent microscope (Olympus IX71) at 20 magniﬁcation.
2.6. Glucose stimulated insulin secretion (GSIS)
EndoC-bH1 cells were seeded at 7  104 cells per well in 96-well
plate (Thermo Scientiﬁc) and cultured for 5 days. EndoC-bH1 pseu-
doislets were aggregated for 5 days and seeded at 50 islets per well in
96-well plates. Both secreted and intracellular amounts of insulin were
measured. For detailed information, see Supplementary Materials and
Methods.
2.7. Perifusion
Perifusion was done on EndoC-bH1 pseudoislets using the Biorep
Perifusion System, version 4.2 (BIOREP technologies, FL, USA). For
detailed information, see Supplementary Materials and Methods.
2.8. Calculations of insulin amounts
To determine the amount of secreted insulin as % of total insulin, the
total insulin content was calculated as the sum of the secreted and the
intracellular insulin after the respective stimulations; ultimately the
value for secreted insulin was divided by the value for total insulin
content. The stimulation index (SI) was calculated as the fold change
between insulin secretion during treatments and the corresponding
insulin secretion at stimulation with low glucose, i.e. 0.5 mM glucose.
For calculation of absolute values of secreted insulin and insulin
content in EndoC-bH1 and human islets, see Supplementary Materials
and Methods.
2.9. Bioinformatics analysis
The bioinformatics analysis performed in this project consisted of
many different parts and while the full details of the in-house drug
target pipeline are classiﬁed, a general overview of the main features
is given here. A bioinformatics toolbox was developed (in perl) that
could store (Oracle) and process all relevant processed data,
including a visual inspection of the most promising candidates (perl
cgi). We started with a comprehensive survey of publicly available
expression data (microarray data, RNA-seq, proteomics, GWAS) from
pancreas, islets, and beta cells as well as tissue proﬁling experi-
ments of biological relevant conditions, which included samples from
humans, animal models, and cell lines. Thereafter, we performed
extensive quality control on each experiment; both of a technical
nature (e.g. FastQC, arrayQualityMetrics) and a biological nature.
Only about 50% of the public experiments were included, and in the
majority of the remaining, at least one sample was excluded. This left
us with 19 relevant public datasets that were used in the down-
stream analysis as a complement to our own in-house generated146 MOLECULAR METABOLISM 8 (2018) 144e157  2017 Novo Nordisk A/S. Published by Elsevier Gmbdata sets. The data was then, among others, via textmining sorted by
annotations for each particular protein, e.g. was there a known link to
Type 2 Diabetes, or diabetes/insulin in general, or any of its co-
morbidities (Non-Alcoholic Fatty Liver Disease, cardiovascular dis-
orders, kidney disease, or hyperlipidemia). Candidates and the dis-
eases were then subjected to an in depth manual curation in which
abstracts from PubMed was read to determine if the link appeared
real. Well over 100.000 abstracts where read in order to ensure the
best possible automatic textmining solution. In addition, traditional
sources of biological annotations, such as Gene Ontology (GO) terms
and UniProt functional descriptions, were also used for conﬁrmation.
In all cases, we integrated all the normalized QCed data on a gene
level (aggregating the signal across multiple lines of evidence) fol-
lowed by a Systems Biology/Network Biology interpretation using a
high-quality ProteineProtein interaction network (InWeb_InBioMap)
[13] as the scaffold for the analysis.
2.10. RNA puriﬁcation, cDNA reverse transcription and real time
PCR
For detailed information, see Supplementary Materials and Methods.
2.11. Single-cell qPCR
EndoC-bH1 (passage number 101) and human islet cells were sorted
by FACS and single cell qPCR was performed on microﬂuidic chips
(Biomark, Fluidigm). Data were analyzed in R (version 3.1.1) and the
analysis consisted of 44 EndoC cells and 17 human islet beta cells. For
detailed information, see Supplementary Materials and Methods.
2.12. Immunocytochemical staining of monolayer cultures and
pseudoislets
For detailed information, see Supplementary Materials and Methods.
2.13. SST-ELISA
SST-ELISA was carried out according to the manufacturer’s procedure
(Antibodies-online GmbH, Cat# E0592h).
2.14. Knock down of GLP1R in EndoC-bH1
To generate a cell line with knock down of GLP1R, ﬁve different
shRNA sequences from the TRC library (SigmaeAldrich, SHCLNV-
NM_002062) were delivered individually by lentiviral transduction
and subsequently grown into stable cell lines using 3 mg/ml Puro-
mycin. The best knockdown was obtained using the TRC clone
NM_002062.2-963s1c1, harboring the shRNA sequence
CCTCATCTTTGTTCGGGTCAT; this cell line was used for the subse-
quent analysis. For comparison, we used a stable cell line expressing
a negative control shRNA from the same lentiviral vector (pLKO.1)
with the shRNA sequence CAACAAGATGAAGAGCACCAA (Sigma,
SHC002V) which targets turboGFP and hence not any known human
mRNA.
2.15. Proliferation assays
The cells were seeded at a density of 4  104 cells per well and
allowed to adhere for 24 h prior to addition of the experimental
compounds: CHIR99021 (Cayman Chemical) or the in-house produced
proteins APOH, SerpineA6 and STC1 (Novo Nordisk). Cells were
stimulated for 24e48 h.
For the 14C-Thymidine incorporation assay, the cells were plated in
scintillation plates (CytoStar-T 96-well, Perkin Elmer) and following
change to experimental media 14C-Thymidine was supplemented to a
ﬁnal concentration 0.5 mCi/ml. The scintillation signal was measured in
a TopCounter NXT HTS instrument (Perkin Elmer).H. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com
For the 5-ethynyl-20-deoxyuridine (EdU) incorporation assay the cells
were plated in black 96-well culture plates (BD-Falcon) and following
change to experimental media the amount of incorporated EdU was
analyzed using the Click-iT EdU Alexa Fluor 488 Imaging Kit (Life
Technologies) according to the manufacturer’s procedure. The cells
were incubated with 0.5 mM EdU for 2 h and subsequently ﬁxed and
stained with DAPI. The EdU signal was quantiﬁed using the InCell
Analyzer 2000 Imaging system (GE Healthcare).
2.16. Apoptosis assay
For the cytokine induced apoptosis assay, the cells were seeded at
4  104 cells per well in 96-well plates and cultured for 48 h prior to
treatment with a cytokine mixture (CytMix) consisting of 1 ng/ml IL-1b,
20 ng/ml IFNg and 20 ng/ml TNFa for 24 h. Caspase 3/7 activity was
measured by use of the ApoTox Triplex or Apo-ONE Caspase 3/7 assay
(Promega) according to the manufacturer’s instructions. All data were
normalized to CytMix treated cells.
For the glucolipotoxicity (palmitate) assay, the cells were seeded at a
density of 5.5  104 cells per well in 96-well plates and 24 h later
treated with increasing amounts of BSA-conjugated palmitate (Echelon
Biosciences) in 20 mM glucose. After 72 h caspase 3/7 activity was
measured using the Apo-ONE Caspase 3/7 assay (Promega).
2.17. Statistics
All statistical analyses are represented an initial unpaired ANOVA fol-
lowed by Student’s t-test. The analysis was performed in GraphPad
Prism version 6.0 and all depicted columns are means and the error
bars are standard error of the mean (SEM), þSEM is shown on top of
each column.
3. RESULTS
3.1. In vivo validation of the EndoC-bH1 cells
To validate the functional capability of the human beta cell line
EndoC-bH1 in vivo, we reproduced the original setup from Rav-
assard et al. and transplanted two million cells under the kidney
capsule of SCID/beige mice made diabetic by STZ mediated beta
cell ablation. During the 42 days long experiment, the transplanted
cells proliferated substantially and protracted out of the boundaries
of the originally transplanted silicone rings (Figure S1A). About six
weeks after transplantation, blood glucose levels in the animals
grafted with EndoC-bH1 decreased to normoglycemic levels
(Figure 1A). Human C-peptide measured three weeks after trans-
plantation was only detected in the animals with EndoC-bH1 cell
transplants (Figure 1B).
Glucose clearance was studied by IPGTT in non-diabetic mice seven
weeks post-transplantation with EndoC-bH1. The cells performed
comparable to 1500 human islet IEQs and much better than 300 IEQs
(Figure 1C). Blood glucose levels in the groups with EndoC-bH1 and
1500 human islet IEQs increased with 5e7 mM after 15 min and then
decreased to 2e4 mM 2 h post glucose administration. In the non-
transplanted animals as well as those transplanted with 300 IEQs,
the blood glucose levels increased at least 2-fold at 30 min prior to
decreasing to a ﬁnal level of 15 mM and 10 mM, respectively. Like-
wise, human C-peptide levels in animals with EndoC-bH1 transplants
or 1500 human IEQs were elevated before the IPGTT and further
increased by the glucose load (Figure 1D).
By histological and immunohistochemical analysis of the EndoC-bH1
grafts from both diabetic (Figure 1E) and non-diabetic (Figure S1B
and C) animals, the transplanted cells were clearly present on top
of the kidney and stained positive for insulin as well as for theMOLECULAR METABOLISM 8 (2018) 144e157  2017 Novo Nordisk A/S. Published by Elsevier GmbH. This is an
www.molecularmetabolism.comvascular marker CD31 and the beta cell speciﬁc transcription factor
Nkx6.1 (data shown for non-diabetic animals in Figure S1C). EndoC-
grafts from diabetic animals stained negative for glucagon while
sporadic SST expression was observed (Figure 1F, top row). The SST
positive cells appeared to be clustered together. Sections from hu-
man islets were stained in parallel as positive controls (Figure 1F,
bottom row).
3.2. Dynamic and static GSIS on EndoC-bH1 monolayers and
pseudoislets
The insulin secretion of EndoC-bH1 monolayer cultures and pseu-
doislets was assessed by perifusion and static GSIS. The appearance
of the generated pseudoislets was uniform, and the cells were highly
viable as evaluated by staining for live (green) and dead (red) cells
(Figure 2A). In addition, they were stained strongly positive for insulin
as demonstrated by immunocytochemistry and subsequent confocal
imaging (Figure 2B).
Perifusion of EndoC-bH1 pseudoislets with low or high glucose
resulted in a single burst of insulin secretion, which declined to
baseline after 30 min despite the continued perifusion with high
glucose (Figure 2C). Addition of the GLP1R agonist Exendin-4 (Ex4),
as expected, led to increased insulin secretion and also led to faster
secretory kinetics compared to glucose alone. This phenomenon was
observed in all experiments. Re-stimulation of the pseudoislets
following a rest period in low glucose resulted in a very modest in-
sulin secretion response (data not shown). The obtained SI during
perifusion was 4-fold between low and high glucose and upon
stimulation with Ex4 and high glucose it increased to 9-fold
(Figure 2D; Table 1).
In regular static GSIS using monolayer cultures, the observed SIs were
2 and 3 for high glucose and high glucose þ Ex4 (Figure 2D, Table 1),
thus the SI using perifusion of pseudoislets was 2e3 folds higher and
this increase in SI was only due to lower insulin secretion in low
glucose and not to higher insulin secretion in high glucose (Figure 2E,
Table 1). To evaluate whether this increased SI obtained during peri-
fusion was due to the perifusion or to the pseudoislet formation, a
static GSIS assay was performed on pseudoislets. We observed a
further decrease in insulin secretion at the low glucose concentration
(Figure 2E) resulting in a further increase of the SI to 2-fold higher than
the SI observed during perifusion and 4-fold higher than what was
observed in monolayer cultures. The obtained SIs and insulin secretion
values are summarized in Table 1.
As reported previously by other groups [4e8], we also found that the
EndoC-bH1 cells secrete insulin in response to glucose and to incretins
(Figure S2A), and that this occurs both under low and high glucose
conditions. However, we were not able to detect the GLP1R protein
despite a substantial effort using several validated antibodies and
mass spectrometry. Thus, in order to show that the cell line contains a
functional GLP1R signaling system, we used the GLP1R antagonist
Exendin9-39 to inhibit the effect of Ex4 (Figure S2B) and by use of
shRNA we reduced the GLP1R mRNA level by 90%, which resulted in a
signiﬁcant decrease of the stimulatory effect of Ex4 (Figure S2C and D),
providing strong evidence for a functional GLP1R pathway in the
EndoC-bH1 cell line.
3.3. Absolute values of secreted insulin and insulin content in
EndoC-bH1 and human islets
The GSIS data obtained in this study were compared to all other studies
reporting the amount of insulin secretion and intracellular content in
EndoC-bH1 monolayer cultures [4,6,7] as well as to a range of data
from human islets [14e19] (Table 2). To do this comparison, we didopen access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 147
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Figure 1: Blood glucose and C-peptide in diabetic and non-diabetic SCID beige mice after transplantation of EndoC-bH1 cells or human islets under the kidney capsule. A) Blood
glucose measurements in STZ induced diabetic SCID beige mice after transplantation of 2 million EndoC-bH1 cells, n ¼ 7 in each group. B) Circulating human C-peptide measured
3 weeks after transplantation, n ¼ 7 in each group. Data shown as mean þ SEM. Measurement of C) blood glucose (at 0, 15, 30, 60, and 120 min) and D) circulating human C-
peptide (at 0 and 60 min) in non-diabetic SCID beige mice during IPGTT performed 6 weeks after transplantation of EndoC-bH1 cells or human islets, n ¼ 5e7 in each group.
Histological analysis: E) Immunohistochemical staining of EndoC-bH1 kidney grafts isolated from diabetic SCID beige mice: Insulin (magenta), CD31 (red) and DAPI (blue). Scale
bar: 1 mm (left), 200 mm (four magniﬁed images on the right). F) Immunohistochemical staining of EndoC-bH1 kidney grafts isolated from diabetic SCID beige mice and human
pancreatic islet section: Insulin (magenta), Glucagon (white), Somatostatin (green) and DAPI (blue). Scale bar: 200 mm.
Original Articlethree approximations regarding cell numbers in the various assay
setups (for details please refer to Supplementary Materials and
Methods). In summary, we ﬁnd that the EndoC-bH1 cells secrete
approximately 5e10% of the insulin amount secreted by human islets
and that the cell line contains around 5% of the insulin content present
in a human islet beta cell.148 MOLECULAR METABOLISM 8 (2018) 144e157  2017 Novo Nordisk A/S. Published by Elsevier GmbMoreover, we noted that the cell line secretes a substantial amount of
pro-insulin especially under low glucose conditions (data not shown).
3.4. Selection of protein and peptide drug candidates for screening
To select for protein and peptides for screening, a comprehensive
bioinformatics analysis was performed with the aim of producing aH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com
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Figure 2: Insulin secretion measured by perifusion and static GSIS on EndoC-bH1 pseudoislets and monolayer cells after stimulation with 0.5 mM glucose (low glucose), 11.2 mM
glucose (high glucose), or in combination with the GLP-1R agonist Ex4, used at 100 nM. A) Staining of EndoC-bH1 pseudoislets with calcein (green) and ethidium homodimer-1
(red), scale bar 500 mm. B) Immunocytochemical staining and confocal imaging of insulin (green), SST (red) and DAPI (grey) in EndoC-bH1 pseudoislets. C) Insulin secretion
measured by perifusion of EndoC-bH1 pseudoislets, 1000 islets per condition; starvation in low glucose performed for 86 min prior to stimulation for 40 min, n ¼ 3. D) SI for
perifusion of EndoC-bH1 pseudoislets (n ¼ 3), for static GSIS in EndoC-bH1 monolayer (n ¼ 9) and pseudoislets (n ¼ 3) based on percent of secreted insulin of total insulin
content; for perifusion SI-calculations were based on AUC/min, for the 38 min stimulation period. E) Insulin secretion measured by perifusion on pseudoislets and static GSIS on
EndoC-bH1 monolayer cells and pseudoislets, n ¼ 3e9. F) Effect of BBs; 10 nM GRP, 10 nM NMB C, 10 nm NMB B32 and 10 nM NMB B on insulin secretion in EndoC-bH1
monolayer cells measured by GSIS, n ¼ 3. G) Effect of 100 nM PACAP 27 and 10 nM PACAP 38 on insulin secretion in EndoC-bH1 monolayer cells measured by static GSIS, n ¼ 3.
Data are shown as mean þ SEM. P-values determined by unpaired One Way ANOVA and Student’s t-test. The # symbol illustrates signiﬁcant difference from low glucose;
#wp < 0.05; ##wp < 0.01. The $ symbol illustrates signiﬁcant difference from low glucose þ Ex-4, $wp < 0.05; $$wp < 0.01. The * symbol illustrates signiﬁcant difference
from high glucose, *wp < 0.05; **wp < 0.01. The  symbol illustrates signiﬁcant difference from high glucose þ Ex-4, wp < 0.05; wp < 0.01.
MOLECULAR METABOLISM 8 (2018) 144e157  2017 Novo Nordisk A/S. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com
149
Table 1 e Summary table on SI and insulin secretion (presented as % of total insulin content) in EndoC-bH1 pseudoislets and monolayer cells during
stimulation with low or high glucose with and without addition of Ex4. SI in EndoC-bH1 pseudoislets is calculated as AUC/min for a 38 min stimulation by
perifusion. The presented values are averages from 3 to 9 independent experiments with 3e4 biological replicates per experiment. Values for amount of
secreted insulin in human islets are obtained during stimulation with low glucose (range 1.8e3.5 mM) and high glucose (range 11.2e27 mM).
EndoC-bH1/human islets Low glucose Low glucose þ Ex-4 High glucose High glucose þ Ex-4
SI Secreted insulin (%) SI Secreted insulin (%) SI Secreted insulin (%) SI Secreted insulin (%)
EndoC-bH1 pseudoislets
Perifusion
e 1.5  0.1 1.5  0.3 2.5  0.4 4.4  0.5 5.3  0.7 9.0  1.7 11.9  2.6
EndoC-bH1 pseudoislets
Static GSIS
e 0.9  0.3 2.4  0.9 2.0  0.7 8.5  3.1 6.7  0.1 14.2  4.7 11.3  1.0
EndoC-bH1 monolayer
Static GSIS
e 4.0  2.0 2.5  0.8 8.0  4.4 2.0  1.1 6.6  1.6 3.3  2.4 10.4  4.2
Human islets (6 studies) e 0.9e2.7 e e e 4.3e8.9 e e
Table 2e Amount of secreted insulin (ng/106 b-cells/stimulation period) and insulin content (mg/106 b-cells/stimulation period) in EndoC-bH1 pseudoislets and
monolayer cultures as well as in human islets during static GSIS and/or perifusion. Stimulation with low glucose, high glucose, or high glucose plus 100 nM Ex4
performed for 1 h (static GSIS) or 40 min (perifusion). Each value is based on results from 2 to 3 independent experiments, with 3e4 biological replicates per
experiment. The insulin amount in EndoC-bH1 monolayer cells and human islets reported from other research groups is shown for comparison. The calculations
regarding human islets are based on the assumption that an islet consists of 1000 cells with 50% of those being beta cells.
Beta cells Secreted insulin (ng/106 b-cells/hr) Insulin content (mg/106 b-cells)
Low glucose (0.5e5 mM) High glucose (11.2e27 mM)
EndoC-bH1
Monolayer cells (this study)
33 60 0.7e1.1
EndoC-bH1
Pseudoislets e perifusion (this study)
9 37 0.6
EndoC-bH1
Pseudoislets e static GSIS (this study)
9 84 1.2
EndoC-bH1
Monolayer cells (Ravassard et al., 2011)
6 19 0.5e0.6
EndoC-bH1
Monolayer cells (Gurgul-Convey et al., 2015)
0.1 1 0.045e0.064
EndoC-bH1
Monolayer cells (Krishnan et al., 2015)
0.1 0.4 8.8
Human islets (6 studies) 250e1300 950e4000 25e95
Original Articleprioritized list of target candidates with the potential of affecting
beta cell functionality, with a focus on GSIS and proliferation. Please
refer to the materials & methods part for further details. In general, a
protein was only considered a target if it was secreted. It was
considered relevant for Type 2 Diabetes biology, for example if it: 1)
interacted with a receptor expressed in beta cells, 2) interacted with
a receptor that is differentially expressed in relevant conditions, 3)
was a novel protein expressed in beta cells, 4) was speciﬁcally
expressed in islets/beta cells. Then, from each category, we ranked
the proteins by different criteria, for example by the fold change in
beta vs alpha cells. Positive selection of candidates was thus based
on known relevance in diabetes for either the target itself, or its
interaction partner(s). In addition, we performed negative ﬁltering to
remove proteins that were not suitable candidates for protein
therapy. These included proteins that in UniProt were annotated as
being expressed in the mitochondria, the endoplasmic reticulum or
that were enzymes, blood factors, extracellular matrix proteins,
major structural proteins, or core immune system proteins (e.g. the
HLA family). Lastly, an evaluation for complexity with regards to
production of the candidate protein was performed. The ﬁnal list
contained well over 300 proteins, of which 228 was tested in vitro,
resulting in identiﬁcation of 16 proteins or peptides that showed a
signiﬁcant biological effect on beta cells.150 MOLECULAR METABOLISM 8 (2018) 144e157  2017 Novo Nordisk A/S. Published by Elsevier Gmb3.5. GSIS screening for insulin secretagogues in EndoC-bH1
monolayer cultures
Among the hundreds of proteins and peptides screened in GSIS (data
not shown), we identiﬁed several compounds with a stimulatory effect.
The most potent induction was observed by the BB receptor agonists
GRP and NMB B32 as well as their concomitant cleavage products
NMB C and NMB B. This induction was evident both as a single
treatment and when administered on top of Ex4 (Figure 2F). Also, clear
dose dependent insulin responses were observed for each of these
four peptides both with and without Ex4 in high glucose but also in low
glucose (Figure S2EeH).
The vasoactive intestinal polypeptides PACAP27 and PACAP38 were
also found to signiﬁcantly stimulate insulin secretion in EndoC-bH1
cells (Figure 2G). Both peptides stimulated insulin secretion already at
10 nM when applied in media with high glucose, alone, and, for
PACAP27, this secretion was further increased by addition of Ex4
(Figure S2I and J).
3.6. Gene and protein expression analysis in EndoC-bH1 compared
to human islets
To investigate potential heterogeneity in EndoC-bH1 and to evaluate
the similarity to human beta cells, mRNA expression in 44 EndoC-bH1
single cells was compared with 17 previously published [20] humanH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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beta cells obtained from the islets of one human donor (Figure 3A). To
determine overall gene expression in the EndoC-bH1 population,
standard qPCR analyses was performed and mRNA levels quantiﬁed in
two different passages of monolayer cultures as well as in pseu-
doislets. These levels were subsequently compared to mRNA levels
obtained from four independent preparations of human islets
(Figure S3).
We found that insulin mRNA expression in EndoC-bH1 cells is lower
than the level in human islets both on single beta cell and islet level,
whereas the important beta cell transcription factors PDX1, PAX6,
FOXA2, NEUROD1, MAFB, NKX6.1, and genes involved in the insulin
secretory machinery like PCSK2 as well as CHGA were expressed at
similar levels or slightly higher compared to human beta cells and islet
preparations (Figure 3A, S3). The glucose transporters SLC2A1-4 were
expressed at low levels in the low passage number EndoC-bH1
monolayer cultures, but, interestingly, SLC2A1 and SCL2A4 were
clearly upregulated in pseudoislets and were found in levels compa-
rable to those in human islets (Figure S3). The expression of GCK in the
EndoC-bH1 monolayer cultures and pseudoislets was found to be 6e7
folds higher than the expression in human islets, while at single cell
level this difference was not noticeable.
Different from the mature human primary beta cells, the ductal cell
marker KRT19 was highly expressed in most of the studied EndoC-bH1
single cells (Figure 3A).
Some of the genes characteristic of adult beta cells were expressed
at very low levels or not detected at all in EndoC-bH1 cells, while
these were readily observed in the studied human beta cells: P2RY1,
HDAC9, GPM6A, RGS16, DLK1, and IAPP (Figure 3B). Overall, the
single cell analysis showed that although many markers in the
EndoC-bH1 cells do not reveal differences between cells, IAP, DLK1,
HDAC9, and P2RY1 reveal that distinct subpopulations do exist
(Figure 3B).
The so-called beta cell disallowed genes including PDGFRA, ITIH5,
SMAD3, ZYX, IGFBP4, and CAT were expressed at similar or lowerA
KRT19
PCSK2
CHGA
NEUROD1
PAX6
PDX1
MAFB
GHRL
SST
PPY
NKX6.1
GCK
PAX4
MAFA
SPRY2
IAPP
P2RY1
PCSK1
HDAC9
DLK1
GPM6A
GCG
RGS16
INS
−2 −1 0 1 2
Global Z Score
Human β-cells
EndoC-βH1
FOXA2
Figure 3: qPCR proﬁling and protein expression in EndoC-bH1. A) Heat map for the expre
beta cells (n ¼ 17). Genes are clustered by Pearson Correlation and samples by normaliz
global SD. B) mRNA expression at single-cell level for 8 selected genes in EndoC-bH1 ce
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www.molecularmetabolism.comlevels compared to human islets, while SLC16A1 (MCT1) and LDHA
were signiﬁcantly higher expressed in the EndoC-bH1 cells [21].
LMO4, a disallowed gene associated with increased cell proliferation
was also found at high levels compared to human islets. As expected,
the proliferation marker Ki67 was highly expressed in EndoC-bH1
monolayer cultures and pseudoislets.
3.7. Expression of non-beta cell markers in EndoC-bH1 cells and
signiﬁcant effect of SST signaling
Transcripts for the non-beta cell markers GCG, PPY, GHRL, AMY2A,
and CFTR were not detected in the EndoC-bH1 cells and immunocy-
tochemical staining of monolayer cell cultures for GCG, PPY, and GHRL
were negative (data not shown).
SST mRNA was observed in a few single cells (Figure 3A) and at
low level in the pooled cultures compared to human islets
(Figure S3). All ﬁve SST receptors were detected in the pools, with
somatostatin receptor 2 (SSTR2) and SSTR5 being expressed at the
highest levels (Figure S3). The SST hormone was clearly detected
at the protein level in approximately 1% of both monolayer cultures
(Figure 4A), pseudoislets (Figure 2B) and in retrieved grafts
(Figure 1F). SST was also found to be secreted into the cell media,
and this appeared to be in a glucose and incretin dependent
manner (Figure 4C). As expected, exogenous SST inhibited the GSIS
response (Figure 4D) but interestingly, inhibition of SSTR2 using the
compound Cyn154806 resulted in a signiﬁcant increase in GSIS,
whereas inhibition of SSTR5 by BIM23056 led to a signiﬁcant
decrease in GSIS (Figure 4D).
3.8. Proliferation screening to identify mitogenic compounds in the
EndoC-bH1 cells
The major difference between EndoC-bH1 cells and mature human
beta cells is their ability to proliferate. The cells have a doubling time of
approximately 7 days, and, before we screened our library of peptides
and proteins, we tested a number of compounds reported to induceB
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Figure 4: SST expression in EndoC-bH1 cells and EndoC-bH1 pseudoislets. A) Immunocytochemical staining for SST (red), insulin (green) and DAPI (blue) in EndoC-bH1 cells,
n ¼ 3. B) SST ELISA in EndoC-bH1 cells, n ¼ 3. C) Effect of 100 nM SST, 100 nM SST-receptor 2 (SSTR2) antagonist Cyn154806, and 1 mM SSTR5-antagonist BIM23056 in
addition to high glucose on insulin secretion in EndoC-bH1 cells, n ¼ 3e8. Data are shown as mean þ SEM, P-values are determined by unpaired One Way ANOVA and Student’s
t-test. The # symbol illustrates signiﬁcant difference from low glucose; #wp < 0.05; ##wp < 0.01. The * symbol illustrates signiﬁcant difference from high glucose,
*wp < 0.05; **wp < 0.01.
Original Articleproliferation in human and mouse beta cells in order to ﬁnd a positive
control for induction of EndoC-bH1 cell proliferation.
We identiﬁed CHIR99021, a GSK3-inhibitor, as the most potent stim-
ulator resulting in a robust, dose-dependent increase in proliferation
rate of EndoC-bH1 by 10e20%. This was observed using two different
proliferation assay setups, 14C-Thymidine- and EdU-incorporation
(Figure 5A, S4A and B).A
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Figure 5: Stimulation of proliferation in EndoC-bH1 cells using the small molecule CHIR99
inhibitor CHIR99021 in concentrations between 0.625 mM and 10 mM with 2-fold increase
48 h treatment, n ¼ 3; each experiment is based on 5e10 replicates for each condition
Thymidine incorporation after 48 h treatment, n ¼ 2e3. Data are shown as mean þ SEM
illustrates signiﬁcant difference from non-treated control cells *wp < 0.05; **wp < 0.0
152 MOLECULAR METABOLISM 8 (2018) 144e157  2017 Novo Nordisk A/S. Published by Elsevier GmbUpon applying our peptide and protein library, we found the pro-
teins SerpinA6, STC1, and APOH induced a 10% increase in pro-
liferation rate of the EndoC-bH1 cells (Figure 5B). A dose titration
with these proteins clearly showed that the effect of SerpinA6 is
dose dependent, and even though the experiment was only per-
formed twice with STC1 and APOH, a similar trend was observed
(Figure S4CeE).B
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3.9. Apoptosis and ER stress assays in EndoC-bH1 cells
Beta cell apoptosis and ER stress are observed in many cases of type 1
and type 2 diabetes [22], and much attention has been focused on
identifying inhibitors of this process for drug development. A classic
mix of cytokines consisting of 1 ng/ml IL-1b, 20 ng/ml IFNg and 20 ng/
ml TNFa signiﬁcantly increased the apoptotic rate in EndoC-bH1 cells
by 3-fold (Figure S5A). The apoptosis inducing effect was conﬁrmed by
use of NMMA and zVAD as partial and complete inhibitors of apoptosis,
respectively. However, upon screening of selected proteins and pep-
tides, we did not observe compounds with protective effect (data not
shown).
The apoptotic effect of palmitate on EndoC-bH1 cells was also
investigated and showed that 3-days treatment with high glucose
(20 mM) and palmitate at concentrations between 0.1 and 0.7 mM do
not have an effect on apoptosis in the EndoC-bH1 cells (Figure S5B).
ER stress was induced by 10 mg/ml tunicamycin for 24 or 48 h and this
resulted in an ample mRNA induction of the classic ER stress genes
HSPA4, DDIT3/CHOP, spliced XBP1 (sXBP1) and also in signiﬁcant
down regulation of insulin mRNA levels (Figure S5C).
4. DISCUSSION
Human beta cells are not recapitulated well by current rodent models,
and more knowledge on the human beta cell is needed in order to
identify novel drug targets as well as potential drug candidates. To
evaluate whether the EndoC-bH1 cells could be useful for identiﬁcation
of proteins and peptides with anti-diabetic properties, we initially
veriﬁed the functionality of the cells both in vitro and in vivo as well as
performed a basic evaluation of mRNA and protein expression of
typical beta and non-beta cell genes. Overall, we found that the cell line
performed satisfactorily and in accordance with data reported in the
original publication [4].
The response of the cell line was tested in four classic assays for beta
cell functionality, namely GSIS, proliferation, apoptosis induced by
cytokines or glucolipotoxic treatment, and induction of ER stress. To
identify positive controls for each assay, we tested the most obvious
candidates and found that Ex4 induced GSIS, that CHIR99021 induced
proliferation and that apoptosis was induced by a mixture of cytokines
(IL-1b, IFNg, TNFa), but not by incubation with the glucolipotoxic
mixture of palmitate and high glucose. For the ER stress assay, the
cells were clearly sensitive to the glycosylation inhibitor Tunicamycin,
as treatment for 24 h resulted in upregulation of the ER stress genes
HSPA4, CHOP and sXBP1, accompanied by a 50% reduction in insulin
mRNA.
4.1. Insulin secretion e validation of the cell line and subsequent
screening
The key measure of beta cell functionality is the GSIS assay. Therefore,
we initially did a thorough examination of the cell line’s ability to
secrete insulin in response to glucose and incretins with regards to
robustness, degree of stimulation (SI) and the stability of this response
over time.
The obtained results clearly showed that in our hands the EndoC-bH1
cell line also reacts robustly to both glucose and incretins, and, when
grown as regular monolayers, the difference in insulin secretion be-
tween low glucose and high glucose plus incretin is on average 3-fold
(Figure 2D, E, Tables 1 and 2). Thus, our data are in line with the
original data from Ravassard et al., 2011 [4]. The absolute amount of
secreted insulin ranges from 10 to 60 ng/106 cells/hr, and the absolute
insulin content is around 1000 ng/106 cells. In comparison to beta cells
from human islets, this is slightly less as they secrete 250e4000 ngMOLECULAR METABOLISM 8 (2018) 144e157  2017 Novo Nordisk A/S. Published by Elsevier GmbH. This is an
www.molecularmetabolism.cominsulin/106 cells/hr and contain around 50,000 ng/106 cells. Thus, in
our hands the EndoC-bH1 cells contain and secrete insulin in the range
of 1e5% of the levels observed in beta cells from human islets.
To initiate a screening for novel proteins and peptides that could
improve beta cell functionality, we performed a bioinformatics analysis
identifying more than 300 proteins and peptides of which we produced
or procured and then tested 228 (refer to Materials and Methods
section for further details). A similar approach based on GWAS data
was published recently and resulted in identiﬁcation of novel roles for
several proteins in human beta cell functionality [23].
Using the GSIS assays, we identiﬁed agonists of the BB receptors as
extremely potent inducers of insulin secretion both under high and low
glucose conditions alone as well as in combination with the GLP1R
agonist Ex4 (Figure 2G). Also, the PACAP peptides stimulate insulin
secretion in high glucose both alone and when co-administered with
Ex4 (Figure 2F), although to a lesser degree thereby more resembling
Ex4 mono therapy.
BB agonist and PACAP are well known secretagogues, which have
been reported to either induce or inhibit insulin as well as glucagon and
SST secretion from human, canine and rodent islets [24e29]. BB
agonists are also known to induce gastrin, CCK and amylase secretion
from the exocrine pancreas [30,31] and have also been shown to
induce GLP1 expression in gut cells [32]. Thus, we substantiate the
already known mode of action of BB agonists and show that the
EndoC-bH1 cells harbor a functional BB receptor signaling system. The
fact that these agonists also induce insulin secretion under low glucose
conditions makes them unattractive as drug candidates. Interestingly,
there was no effect of the PACAP peptides in low glucose indicating
that these peptides may be true glucose sensitive secretagogues.
However, in our hands neither the four BB agonists nor the two PACAP
peptides showed an effect on blood glucose levels when administered
i.p. to db/db mice (data not shown). It is plausible that this lack of effect
could be due to induction of simultaneous secretion of glucagon as
well as insulin in the db/db model. Others are currently attempting to
develop PACAP analogs without glucagon secreting properties as a
potential drug for treatment of diabetes [33]. Otherwise, the lack of
effect on blood glucose could be due to a difference in functionality of
these particular peptides between human and mouse species. Future
studies could investigate the effect of the peptides in transplanted
human islets.
Moreover, PACAP has been reported to induce beta cell proliferation
and mediate protection against apoptosis [34], but we did not ﬁnd
proliferative or apoptosis protecting effects of the PACAP peptides in
the EndoC-bH1 cells. Lastly, PACAP peptides have been reported to
have undesirable secretory effects on the exocrine pancreas, which
could lead to increased risk of pancreatitis [35].
4.2. Proliferation e search of a positive control and subsequent
screening
To induce proliferation in the EndoC-bH1 cells, we initially tested a
number of published molecules (CHIR99021, BIO, 1-AKP, Harmine,
INDY, WS6 and Denosumab) and found CHIR99021 to exert the most
robust effect, leading to a 10e20% induction of growth rate. Whether
compounds that induce proliferation in the EndoC-bH1 cells have a
similar effect on human islets remains an important question to pursue
in the future. Since GSK3 inhibition has been shown to induce prolif-
eration in both rodent [36] and human islet beta cells [16], this may also
be the case for other compounds despite inhibition of GSK3 alone may
not always lead to increased proliferation in human islet beta cells [37].
In our screening using the thymidine incorporation assay, we found the
proteins SerpinA6, STC1 and APOH to marginally but signiﬁcantlyopen access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 153
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family of serine protease inhibitors consisting of 16 clades of proteins
(named from A to P). SerpinB1, a member of the B clade, has been
shown to increase beta cell proliferation in human islets [38], thereby
suggesting a role for the serine protease inhibitor superfamily in
pancreatic beta cell proliferation. Furthermore, SerpinA6 has been
associated with resistance to chemotherapy in patients with breast
cancer [39] and human hepatocellular carcinoma [40], also indicative
of a role in proliferation. Future studies should investigate whether this
protein also has a mitogenic effect on beta cells from human islets.
STC1 is a known oncogene [41] and APOH is widely expressed in the
body and involved in numerous biological processes that we did not
ﬁnd these proteins relevant for further investigations in the context of
drug discovery.
4.3. Apoptosis e investigation of potential assays and subsequent
screening
To assess the level of apoptosis in the EndoC-bH1 cells under
diabetes-like conditions, we treated the cells with either palmitate and
high glucose (glucolipotox) or pro-inﬂammatory cytokines and then
measured the induction of caspase 3/7 activity. For the glucolipotoxic
stress, three days of treatment with 0.1e0.7 mM palmitate in the
presence of 20 mM glucose did not initiate apoptotic cell death in the
EndoC-bH1 cells. Similar results were obtained in a recent study using
1 mM palmitate and 22 mM glucose [42]. Interestingly, in the same
study it was found that the use of 1.5e2 mM palmitate resulted in an
increase in cell death already at day 1 and that use of the more nutrient
rich culture medium DMEM/Ham’s F12 signiﬁcantly increased palmi-
tate induced cell death even at normal glucose level (5.5 mM). Simi-
larly, glucolipotoxicity studies on human islets have shown no effect of
0.5 mM or 1 mM palmitate after 2e3 days of treatment [43,44],
whereas a signiﬁcant effect was observed after 6e7 days of treatment
[43,45]. This indicates that a longer treatment period is necessary to
induce an apoptotic effect in human islets and therefore potentially also
in EndoC-bH1 cells. However, from a screening point of view, we
conclude that an assay duration of 7e10 days is too long to be useful.
Nevertheless, the use of DMEM/F12 and further optimization of the
culture conditions seem very promising for the use of EndoC-bH1 cells
for lipotoxicity studies.
Interestingly, the cells are clearly responsive to cytokines as 24 h of
treatment with a mixture of IL1b, IFNg, and TNFa resulted in a 3-fold
increase in caspase-3/7 activity. We used this assay to screen more
than 100 proteins and peptides, but without observing signiﬁcant
protective effects of the compounds tested. Nevertheless, the EndoC-
bH1 cell line reacts to cytokines in a manner similar to human beta
cells and the assay is valuable for further investigations.
Induction of ER stress with Tunicamycin resulted in signiﬁcant effects
comparable to what is observed in human and mouse islet beta cells
[46,47]. Moreover, the assay is fast and reproducible and therefore
highly compatible with high-through put screening, and we are
currently testing our compounds in this assay. However, this assay
may be less biological relevant due to the harsh effect of Tunicamycin,
and it may also represent an earlier stage of diabetes and hence be
more relevant for identiﬁcation of drug candidates to be used for
prevention of diabetes rather than for treatment of the disease.
4.4. Perifusion of pseudoislets
Perifusion of pseudoislets resulted in a dramatic increase of the GSIS
window, i.e. at the point of maximal secretion; a GSIS window of
approximately 20- and 45-fold was observed for high glucose and high
glucoseþ Ex4 compared to low glucose (Figure 2C), respectively. This154 MOLECULAR METABOLISM 8 (2018) 144e157  2017 Novo Nordisk A/S. Published by Elsevier Gmbincrease was even more noticeable in static GSIS on the pseudoislets
(Figure 2D, Table 1), and, from analysis of the total amount of secreted
insulin (Figure 2E), it became apparent that the increased GSIS window
is due to decreased insulin secretion at low glucose in the pseudo-
islets compared to monolayer cultures and not related to the peri-
fusion method. Thus, in our hands aggregation of EndoC-bH1 cells into
pseudoislets results in a highly reproducible drop in insulin secretion
under low glucose conditions, which leads to an increase in the static
GSIS assay window of approximately 4-fold (Figure 2D, Table 1).
Pseudoislets from beta cell lines have been generated previously, and
a similar 4-fold increase in response to glucose was observed in the
EndoC-bH3 cell line following aggregation into pseudoislets. This
occurred despite their method of aggregation was quite different from
ours [48]. Also, equivalent observations have been reported using the
mouse beta cell line bTC3 [49].
Overall, the possibility of having a large GSIS assay window in a human
setting is desirable for identiﬁcation of potential drug candidates with
more modest stimulatory effect on insulin secretion. Handling of the
pseudoislets is more challenging compared to regular monolayer
cultures, and, hence, we did not ﬁnd it applicable for the screening
assays.
4.5. Gene expression e markers of maturity and expression
homogeneity
Single-cell qPCR was used to evaluate the degree of homogeneity of
the EndoC-bH1 cell line and to make a direct comparison of mRNA
expression levels to beta cells from human islets (Figure 3). To analyze
the EndoC-bH1 cells for expression of genes known to be important for
beta cell identity, function, and maturity, we performed qPCR analysis
of selected mRNAs on regular pools of EndoC-bH1 cells, both as
monolayer cultures at early and late passage numbers and as pseu-
doislets. To compare directly to the mRNA levels found in human islets,
we performed parallel qPCR on four different preparations of human
islets (Figure S3).
Overall, we found the general expression pattern of the investigated
mRNAs to be quite similar between EndoC-bH1 and human islets.
However, with expression levels in the EndoC-bH1 cells being a bit
lower for some of genes linked to beta cell identity. For example: PDX1,
PAX4, PAX6, FOXA2, NeuroD1, MAFB, NKX6.1, KCNJ11, PCSK1/2, and
CHGA, an observation that is supported by the original publication [4].
Most mRNAs were expressed at a stable level over time (low vs. high
passage number) and when aggregated to pseudoislets. However,
there were also some interesting changes, such as the glucose
transporters SLC2A1/GLUT1 and SLC2A4/GLUT4, which were
expressed at higher levels in pseudoislets, potentially explaining the
reduction in insulin secretion under low glucose in the pseudoislets.
Also, the MafB mRNA was expressed at higher levels in EndoC-bH1
pseudoislets, which is in accordance with the known presence of MafB
in adult human beta cells [50,51]. In contrast,MafA did not change and
remained low at all times. Moreover, we found clear expression of the
so-called disallowed genes [21] SLC16A1/MCT1 and LDHA in EndoC-
bH1 compared to human islets (Figure S3). SLC16A1 and LDHA are
important for nutrient sensing in non-beta cells and hence repressed in
adult beta cells to prevent inappropriate insulin secretion [52]. The
aberrant expression of these genes may be involved in the observed
insulin secretion in low glucose and the relatively small GSIS window of
EndoC-bH1 monolayer cultures.
By single cell qPCR, we found EndoC-bH1 cells to be quite homoge-
neous (Figure 3A), despite some variation in expression between cells
was also observed for some genes (Figure 3B). For example the mRNA
expression level of the genes IAPP, DLK1, HDAC9, P2RY1, GPM6A, andH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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RGS16 were lower and more heterogeneous in EndoC-bH1 cells than
in beta cells from human islets (Figure 3B). These genes are known to
be expressed in adult, and thus non-proliferating, beta cells [53] and to
be fully absent or expressed at lower levels in young or fetal beta cells
[54]. Also, most of the EndoC-bH1 cells express the ductal marker
KRT19 at single cell level, which could also be indicative of a beta cell
in an earlier stage of development [55]. Interestingly, HDAC9 was also
recently been found to be differentially expressed between sub-
populations of beta cells within individual human donors [56].
Overall, these ﬁndings likely reﬂect the proliferative status of the
EndoC-bH1 cell line and hence the expected fate towards a slightly
immature genotype due to this forced proliferation.
4.6. SST e expression and functional consequence
We found the SST protein to be expressed in approximately 1% of the
EndoC-bH1 cells as well as secreted in signiﬁcant amounts. Also,
mRNA from all ﬁve SST receptors (SSTR1-5) were detected with
SSTR2 and SSTR5 being the most abundant. In accordance with SST
being an inhibitory hormone, treatment with exogenous SST leads to a
clear reduction in GSIS. Interestingly, inhibition of SSTR2 or SSTR5
using the small modiﬁed peptides CYN154806 and BIM23056,
respectively led to strong but opposite effects on GSIS (Figure 4D).
Furthermore, treatment with the pan SSTR1-5 inhibitor peptide cyclo-
SST also resulted in inhibition of GSIS (data not shown), i.e. similar to
the natural SST agonist. This suggests that a strong differential effect
on signaling exists between the ﬁve SST receptors in the EndoC-bH1
cells and this phenomenon warrants further exploration.
In an attempt to reduce or remove this aberrant expression, we
generated several stable cell lines with knockdown of SST and/or
SSTR2. Even with a 70% knockdown of SST or SSTR2 mRNA we did
not observe any change in GSIS response (data not shown). This is
likely due to the remaining SST being able to sustain adequate
signaling and future studies could apply gene editing to completely
remove the SST expression. Finally, we did not ﬁnd SST or CYN154806
to modulate proliferation or apoptosis.
The fact that EndoC-bH1 cells express SST could be mediated by
incomplete recruitment of transcription factors during differentiation
due to the relatively short rat insulin promotor sequence used to drive
proliferation of the fetal pancreatic cell buds used to develop the
EndoC-bH1 cell line.
4.7. In vivo functionality
Upon transplantation of two million EndoC-bH1 cells to STZ induced
diabetic SCID/Beige mice, the grafted cells clearly produce sufﬁcient
insulin to restore normoglycemia, and human C-peptide is evident only
in the animals with EndoC-bH1 transplants. This demonstrates both
production and function of human insulin in the transplanted mice with
an outcome equivalent to 1500 human islets. The normalization of
blood glucose occurs around six weeks post-transplantation and, thus,
vascularization as well as proliferation of the cells in vivo is likely a
prerequisite. In an i.p. glucose challenge performed six weeks after
transplantation, the grafted cells cleared the glucose in a manner
comparable to 1500 human islet IEQs, which was accompanied by an
increase in C-peptide secretion. However, we had to terminate the
mice 7e8 weeks after the transplantation due to hypoglycemia and we
speculate that the insulin secretion in vivo is ongoing in a constant
fashion and that the amount of secreted insulin may be more related to
the number of transplanted cells present in the mouse rather than the
actual glucose level. Regarding hormone expression, the grafted cells
appeared similar post-transplantation as compared to standard in vitro
cultured cells.MOLECULAR METABOLISM 8 (2018) 144e157  2017 Novo Nordisk A/S. Published by Elsevier GmbH. This is an
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We have investigated the EndoC-bH1 cell line with regard to func-
tionality and general beta and non-beta cell marker expression and
conclude that it is a valid cell line model of human beta cells. We have
successfully used it as a screening platform for early drug discovery
with regards to insulin secretion and beta cell proliferation and iden-
tiﬁed several interesting peptides and proteins. Furthermore, the cell
line is also of interest for screening compounds with beneﬁcial effect
on ER stress and to assess more in depth the importance of the ﬁve
SST receptors and their interplay in the context of insulin secretion.
Thus, we conclude that the EndoC-bH1 cell line is a functional and
valid human beta cell line that can be efﬁciently applied as a screening
platform for novel anti-diabetic drug candidates with the aim of
achieving higher probability of the candidates to show an effect on real
human beta cells.
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